Expanded Access to the Oral Pan-RAF Inhibitor DAY101 in Pediatric Patients with RAF-Altered, Relapsed or Refractory Low-Grade Glioma.
| Protocol No. | PHO-DOB-DAY101-EAP | Scope | National |
|---|---|---|---|
| Principal Investigator | Daniel Runco | Treatment Type | Treatment |
| Age Group | Adults and Children | Phase | NA |
